BioSpace News Archive

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2020, and provided business updates.

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors.

Demand for chromatography syringes has foreseen an upsurge on account of varying regulatory framework, together with the increase in consumer concerns regarding food safety.

Aspartate Aminotransferase is a key enzyme of amino acid metabolism that catalyzes the reversible transfer of the amine group from L-aspartate to 2-oxoglutarate.

With technological advancements in the worldwide healthcare sector, there is remarkable growth in acceptance of blood collection tubes for liquid biopsy in a wide range of applications including research activities and vitro diagnostics.

Electric bed enables changing the position of both the upper and lower body and adjust the bed height itself. It can also help with a number of medical conditions.

Bulimia nervosa refers to a type of eating disorder linked with binge eating following compensatory processes.

Ultimovacs ASA, announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca, to conduct a randomized Phase II clinical trial to evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab and olaparib in patients with relapsed ovarian cancer.

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced a business update for the fourth quarter 2020 and certain preliminary, unaudited key financials for its financial year 2020.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced preliminary financial results for the fourth quarter and full-year 2020, with U.S. revenues expected to reflect a growth range of 7% to 8%.